-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-Casi Pharmaceuticals And Cleave Therapeutics Announce Clinical Trial Application Approval For CB-5339

Reuters · 01/06/2023 07:13
BRIEF-Casi Pharmaceuticals And Cleave Therapeutics Announce Clinical Trial Application Approval For CB-5339

- CASI Pharmaceuticals Inc CASI.O:

  • CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

  • CASI PHARMACEUTICALS INC: EXPECTED ENROLLMENT TO BEGIN IN 2023

Source text for Eikon: ID:

Further company coverage: CASI.O


((Reuters.Briefs@thomsonreuters.com;))